Soligenix的库存在FDA指定用于Behçet病治疗的孤儿药物之后猛增。 Soligenix's stock skyrocketed after the FDA's orphan drug designation for its Behçet's disease treatment.

Soligenix的库存超过50%, 是因为FDA将孤儿药物命名为SGX945 治疗Behçet病(一种罕见的煽动性紊乱症)。 Soligenix's stock surged over 50% after the FDA granted orphan drug designation to its SGX945 treatment for Behçet's disease, a rare inflammatory disorder. 指认是在第2阶段a研究结果显示安全性和有效性之后进行的。 The designation followed positive Phase 2a study results showing safety and efficacy. 美国食品和药物管理局的孤儿药物计划支持治疗少于20万名患者的罕见疾病, 提供市场独家权和经济激励. The FDA's orphan drug program supports treatments for rare diseases with fewer than 200,000 patients, offering market exclusivity and financial incentives.